Oz Medicann Group (OMG) has struck a deal to accelerate the development and commercialisation of cannabinoid medicines across Asia.
The agreement will see South Korea-based biotech NeoCannBio (NCB) receive exclusive rights to distribute products emerging from clinical trial data generated by OMG.
The Australian firm said data from trials will support “parallel clinical programs and regulatory pathways across Asia, enabling more efficient market authorisation and faster access to evidence-based therapies”.
Target markets in the region will exclude China and India.
OMG founder John Leith said the collaboration “reflects growing international confidence in Australian clinical research, regulatory standards, and innovation”.
“By combining Australian science with strong regional partners, we are creating a responsible and scalable pathway to address real patient needs globally, while ensuring that intellectual property and clinical leadership remain Australian,” he said.
Group chief executive Rohit Bhuta said OMG has multiple clinical trials underway, including projects to support potential schedule 3, over-the-counter regulatory pathways.
“This partnership enables NeoCannBio to leverage Australian clinical evidence to expedite registration discussions with regulators across Asia, potentially simplifying the pathway for patients to access clinically validated products without prescription,” he said.
Bhuta said similar deals are being explored in other global regions as OMG seeks to build a “scalable, international pathway anchored in Australian science”.
NeoCannBio president Jeong Kook Kim described the move as a “long-term strategic alignment that combines Australian clinical excellence with our regional development and commercial capabilities”.
“Together, we aim to deliver meaningful healthcare solutions across Asia while maintaining the highest standards of science, governance, and regulatory compliance,” he said.
OMG is advancing a number of clinical trials covering sleep disorders, endometriosis, arthritis, and skin fungal infections.